Skip to main content
SpringerLink
Log in

Gesundheitsökonomie und Lebensqualität bei Epilepsie

Health economics and quality of life in epilepsy

  • Leitthema
  • Published:
Zeitschrift für Epileptologie Aims and scope Submit manuscript

Zusammenfassung

Die Epilepsie ist eine der häufigsten chronischen neurologischen Erkrankungen und stellt für die Betroffenen, die Angehörigen und für die Gesellschaft eine erhebliche Belastung dar. Studien zeigen im Wesentlichen hohe Kosten für stationäre Behandlungen und Medikamente bei neu diagnostizierten Patienten sowie bei therapierefraktären Patienten und der dabei meist notwendigen Polytherapie. Die antikonvulsive Therapie erfolgt vorwiegend mit Valproat, Carbamazepin, Lamotrigin oder Levetiracetam. Die Erkrankung führt zu negativen Auswirkungen auf die Berufstätigkeit und damit verbundenen hohen indirekte Kosten. Die Lebensqualität ist deutlich eingeschränkt, wenn Anfälle persistieren. Therapeutische Entscheidungen bei medikamentösen wie operativen Maßnahmen müssen die Lebenswirklichkeit der Patienten in unterschiedlichen Lebensabschnitten im Blick behalten, um eine umfassende Behandlung zu ermöglichen.

Abstract

Epilepsy is a common chronic neurological disease and represents a significant burden for patients, their families, and society. Cost-of-illness studies show high hospital and drug costs for newly diagnosed and drug-refractory patients needing polytherapy. Anticonvulsant therapy still consists mainly of valproate, carbamazepine, lamotrigine, or levetiracetam. Epilepsy leads to negative effects on employment with high indirect costs. Quality of life is reduced when seizures persist. Therapeutic decisions with respect to anticonvulsive therapy and surgery should focus on the patient’s daily reality in the different phases of life to allow for a comprehensive treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Forsgren L, Beghi E, Oun A, Sillanpaa M (2005) The epidemiology of epilepsy in Europe – a systematic review. Eur J Neurol 12:245–253

    Article  CAS  PubMed  Google Scholar 

  2. Forsgren I, Beghi E, Ekman M (2005) Cost of epilepsy in Europe. Eur J Neurol 12(Suppl 1):54–58

    Article  PubMed  Google Scholar 

  3. Strzelczyk A, Reese JP, Dodel R, Hamer HM (2008) Cost of epilepsy: a systematic review. Pharmacoeconomics 26:463–476

    Article  PubMed  Google Scholar 

  4. Kotsopoulos IA, Evers SM, Ament AJ, Krom MC de (2001) Estimating the costs of epilepsy: an international comparison of epilepsy cost studies. Epilepsia 42:634–640

    Article  CAS  PubMed  Google Scholar 

  5. Dodel RC, Pepperl S, Kohne-Volland R et al (1996) Kosten der medikamentösen Behandlung neurologischer Erkrankungen: Morbus Parkinson, Dystonie, Epilepsie. Med Klin (München) 91:479–485

    Google Scholar 

  6. Hout B van, Gagnon D, Souetre E et al (1997) Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdom. Epilepsia 38:1221–1226

    Article  PubMed  Google Scholar 

  7. Schöffski O, Graf von der Schulenburg J.-M. (Hrsg.) (2007) Gesundheitsökonomische Evaluationen. 3. vollständig überarb. Aufl. Springer, Berlin Heidelberg

  8. Rice DP (1994) Cost-of-illness studies: fact or fiction? Lancet 344:1519–1520

    Article  CAS  PubMed  Google Scholar 

  9. Henke K-D, Martin K, Behrens C (1997) Direkte und indirekte Kosten von Krankheiten in der Bundesrepublik Deutschland 1980 und 1990. Z Gesundh Wiss 5:123–145

    Article  Google Scholar 

  10. Hamer HM, Strzelczyk A, Dodel R (2011) Direkte und indirekte Kosten der Epilepsie. Z Epileptol 24:172–177

    Article  Google Scholar 

  11. Beran RG (1999) The burden of epilepsy for the patient: the intangible costs. Epilepsia 40(Suppl 8):40–43

    Article  PubMed  Google Scholar 

  12. Hamer HM, Spottke A, Aletsee C et al (2006) Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 47:2165–2172

    Article  PubMed  Google Scholar 

  13. Noda AH, Hermsen A, Berkenfeld R et al (2015) Evaluation of costs of epilepsy using an electronic practice management software in Germany. Seizure 26:49–55

    Article  PubMed  Google Scholar 

  14. Noda AH, Reese JP, Berkenfeld R et al (2015) Leitlinienumsetzung und Kosten bei neudiagnostizierter Epilepsie. Z Epileptol 28. DOI 10.1007/s10309-015-0419-1

  15. Rychlik R, Runge U, Peckmann T, Lohmüller K (2010) Krankheitskosten der Epilepsie. Ressourcenverbrauch durch Epilepsiepatienten in Mecklenburg-Vorpommern. Z Epileptol 23:114–118

    Article  Google Scholar 

  16. Strzelczyk A, Haag A, Reese JP et al (2013) Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav 27:433–438

    Article  PubMed  Google Scholar 

  17. Strzelczyk A, Nickolay T, Bauer S et al (2012) Evaluation of health-care utilization among adult patients with epilepsy in Germany. Epilepsy Behav 23:451–457

    Article  PubMed  Google Scholar 

  18. Strzelczyk A, Reese JP, Oertel WH et al (2013) Costs of epilepsy and their predictors: cross-sectional study in Germany and review of literature. Epileptology 1:55–60

    Article  Google Scholar 

  19. Strzelczyk A, Schubert-Bast S, Reese JP et al (2014) Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Epilepsy Behav 34:86–91

    Article  PubMed  Google Scholar 

  20. Johannessen Landmark C, Fossmark H, Larsson PG et al (2011) Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res 95:51–59

    Article  PubMed  Google Scholar 

  21. Tsiropoulos I, Gichangi A, Andersen M et al (2006) Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand 113:405–411

    Article  CAS  PubMed  Google Scholar 

  22. Beghi E, Garattini L, Ricci E et al (2004) Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 45:171–178

    Article  PubMed  Google Scholar 

  23. De Zelicourt M, Buteau L, Fagnani F, Jallon P (2000) The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Active coordination of the longitudinal observational network in epilepsy. Seizure 9:88–95

    Article  Google Scholar 

  24. Tetto A, Manzoni P, Millul A et al (2002) The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res 48:207–216

    Article  CAS  PubMed  Google Scholar 

  25. Kortland LM, Knake S, Rosenow F, Strzelczyk A (2015) Cost of status epilepticus: a systematic review. Seizure 24:17–20

    Article  PubMed  Google Scholar 

  26. Gilliam F, Kuzniecky R, Faught E et al (1997) Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia 38:233–236

    Article  CAS  PubMed  Google Scholar 

  27. Strzelczyk A, Hermsen A, Oertel WH et al (2014) Epilepsiebedingte Verletzungen und Unfälle. Risikofaktoren und Häufigkeit. Nervenheilkunde 33:331–334

    Google Scholar 

  28. Begley CE, Annegers JF, Lairson DR et al (1994) Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 35:1230–1243

    Article  CAS  PubMed  Google Scholar 

  29. Cockerell OC, Hart YM, Sander JW, Shorvon SD (1994) The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 18:249–260

    Article  CAS  PubMed  Google Scholar 

  30. Jennum P, Gyllenborg J, Kjellberg J (2011) The social and economic consequences of epilepsy: a controlled national study. Epilepsia 52:949–956

    Article  PubMed  Google Scholar 

  31. Krishnan A, Sahariah SU, Kapoor SK (2004) Cost of epilepsy in patients attending a secondary-level hospital in India. Epilepsia 45:289–291

    Article  PubMed  Google Scholar 

  32. Mak W, Fong JK, Cheung RT, Ho SL (1999) Cost of epilepsy in Hong Kong: experience from a regional hospital. Seizure 8:456–464

    Article  CAS  PubMed  Google Scholar 

  33. Murray MI, Halpern MT, Leppik IE (1996) Cost of refractory epilepsy in adults in the USA. Epilepsy Res 23:139–148

    Article  CAS  PubMed  Google Scholar 

  34. Thomas SV, Sarma PS, Alexander M et al (2001) Economic burden of epilepsy in India. Epilepsia 42:1052–1060

    Article  CAS  PubMed  Google Scholar 

  35. Haag A, Strzelczyk A, Bauer S et al (2010) Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of „newer“ versus „classic“ drugs: results of the „Compliant 2006“ survey in 907 patients. Epilepsy Behav 19:618–622

    Article  CAS  PubMed  Google Scholar 

  36. Smeets VM, Lierop BA van, Vanhoutvin JP et al (2007) Epilepsy and employment: literature review. Epilepsy Behav 10:354–362

    Article  PubMed  Google Scholar 

  37. Pfäfflin M, May T, Stefan H, Adelmeier U (2000) Epilepsiebedingte Beeinträchtigungen im täglichen Leben und in der Erwerbstätigkeit – Querschnittsstudie an Patienten niedergelassener Ärzte. Neurol Rehabil 6:140–148

    Google Scholar 

  38. Hamer HM, Dodel R, Strzelczyk A et al (2012) Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany – a nationwide population-based study in children and adults. J Neurol 259:2376–2384

    Article  PubMed  Google Scholar 

  39. Dorks M, Langner I, Timmer A, Garbe E (2013) Treatment of paediatric epilepsy in Germany: antiepileptic drug utilisation in children and adolescents with a focus on new antiepileptic drugs. Epilepsy Res 103:45–53

    Article  PubMed  Google Scholar 

  40. Hamer HM, Kostev K (2014) Sociodemographic disparities in administration of antiepileptic drugs to adults with epilepsy in Germany: a retrospective, database study of drug prescriptions. CNS Drugs 28:753–759

    Article  CAS  PubMed  Google Scholar 

  41. Gunthorpe MJ, Large CH, Sankar R (2012) The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 53:412–424

    Article  CAS  PubMed  Google Scholar 

  42. Steinhoff BJ, Ben-Menachem E, Ryvlin P et al (2013) Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 54:1481–1489

    Article  CAS  PubMed  Google Scholar 

  43. Steinhoff BJ, Hamer H, Trinka E et al (2014) A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res 108:986–988

    Article  CAS  PubMed  Google Scholar 

  44. Drummond M (1992) Cost-of-illness studies: a major headache? Pharmacoeconomics 2:1–4

    Article  CAS  PubMed  Google Scholar 

  45. Thorbecke R, May TW, Koch-Stoecker S et al (2014) Effects of an inpatient rehabilitation program after temporal lobe epilepsy surgery and other factors on employment 2 years after epilepsy surgery. Epilepsia 55:725–733

    Article  PubMed  Google Scholar 

  46. Schulz J, Beicher A, Mayer G et al (2013) Counseling and social work for persons with epilepsy: observational study on demand and issues in Hessen, Germany. Epilepsy Behav 28:358–362

    Article  PubMed  Google Scholar 

  47. Kerr MP (2012) The impact of epilepsy on patients‘ lives. Acta Neurol Scand Suppl 194:1–9

    Article  PubMed  Google Scholar 

  48. Bishop M, Allen CA (2003) The impact of epilepsy on quality of life: a qualitative analysis. Epilepsy Behav 4:226–233

    Article  PubMed  Google Scholar 

  49. Jacoby A (1992) Epilepsy and the quality of everyday life. Findings from a study of people with well-controlled epilepsy. Soc Sci Med 34:657–666

    Article  CAS  PubMed  Google Scholar 

  50. Livneh H, Wilson LM, Duchesneau A, Antonak RF (2001) Psychosocial adaptation to epilepsy: the role of coping strategies. Epilepsy Behav 2:533–544

    Article  PubMed  Google Scholar 

  51. Devinsky O (2000) The meaning of quality of life to patients with epilepsy. Epilepsy Behav 1:S18–S20

    Article  CAS  PubMed  Google Scholar 

  52. Birbeck GL, Hays RD, Cui X, Vickrey BG (2002) Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 43:535–538

    Article  PubMed  Google Scholar 

  53. Gilliam F, Hecimovic H, Sheline Y (2003) Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav 4(Suppl 4):S26–S30

    Article  PubMed  Google Scholar 

  54. Lehrner J, Kalchmayr R, Serles W et al (1999) Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients. Seizure 8:88–92

    Article  CAS  PubMed  Google Scholar 

  55. Bautista RE, Glen ET (2009) Seizure severity is associated with quality of life independent of seizure frequency. Epilepsy Behav 16:325–329

    Article  PubMed  Google Scholar 

  56. Sancho J, Ivanez V, Molins A et al (2010) Changes in seizure severity and quality of life in patients with refractory partial epilepsy. Epilepsy Behav 19:409–413

    Article  PubMed  Google Scholar 

  57. Jacoby A, Baker GA, Steen N et al (1996) The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study. Epilepsia 37:148–161

    Article  CAS  PubMed  Google Scholar 

  58. Beghi E, Cornaggia C, Group RE (2002) Morbidity and accidents in patients with epilepsy: results of a European cohort study. Epilepsia 43:1076–1083

    Article  PubMed  Google Scholar 

  59. Pugh MJ, Copeland LA, Zeber JE et al (2005) The impact of epilepsy on health status among younger and older adults. Epilepsia 46:1820–1827

    Article  PubMed  Google Scholar 

  60. Baker GA, Jacoby A, Buck D et al (2001) The quality of life of older people with epilepsy: findings from a UK community study. Seizure 10:92–99

    Article  CAS  PubMed  Google Scholar 

  61. Haut SR, Katz M, Masur J, Lipton RB (2009) Seizures in the elderly: impact on mental status, mood, and sleep. Epilepsy Behav 14:540–544

    Article  PubMed  PubMed Central  Google Scholar 

  62. Johnson EK, Jones JE, Seidenberg M, Hermann BP (2004) The relative impact of anxiety, depression, and clinical seizure features on health-related quality of life in epilepsy. Epilepsia 45:544–550

    Article  PubMed  Google Scholar 

  63. Ramsay RE, Rowan AJ, Pryor FM (2004) Special considerations in treating the elderly patient with epilepsy. Neurology 62:S24–S29

    Article  PubMed  Google Scholar 

  64. Luoni C, Bisulli F, Canevini MP et al (2011) Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia 52:2181–2191

    Article  PubMed  Google Scholar 

  65. Karceski SC (2007) Seizure medications and their side effects. Neurology 69:E27–E29

    Article  PubMed  Google Scholar 

  66. Sillanpaa M, Haataja L, Shinnar S (2004) Perceived impact of childhood-onset epilepsy on quality of life as an adult. Epilepsia 45:971–977

    Article  PubMed  Google Scholar 

  67. Markand ON, Salanova V, Whelihan E, Emsley CL (2000) Health-related quality of life outcome in medically refractory epilepsy treated with anterior temporal lobectomy. Epilepsia 41:749–759

    Article  CAS  PubMed  Google Scholar 

  68. Wilson SJ, Saling MM, Kincade P, Bladin PF (1998) Patient expectations of temporal lobe surgery. Epilepsia 39:167–174

    Article  CAS  PubMed  Google Scholar 

  69. Gilliam F, Kuzniecky R, Meador K et al (1999) Patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy. Neurology 53:687–694

    Article  CAS  PubMed  Google Scholar 

  70. Langfitt JT, Westerveld M, Hamberger MJ et al (2007) Worsening of quality of life after epilepsy surgery: effect of seizures and memory decline. Neurology 68:1988–1994

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. H.M. Hamer hat als Berater der Firmen Cerbomed, Desitin, Eisai, GSK, Pfizer und UCB Pharma Honorare erhalten. Darüber hinaus hat er Rednerhonorare und/oder Unterstützungen für Fortbildungsveranstaltungen erhalten von Desitin, Eisai, GSK, Nihon Kohden, Novartis, Pfizer und UCB Pharma sowie von den Universitäten Essen, Hamburg, Hannover, Marburg, München und Saarbrücken. Er erhielt Unterstützung für Forschungsvorhaben von Desitin, Janssen-Cilag, GSK und UCB Pharma. A. Strzelczyk erhielt Beratungs- und Referentenhonorare von Bayer HealthCare, Boehringer Ingelheim, Desitin, Eisai, Pfizer und UCB Pharma. J.D. Lang, S. Richter und N. Watermann geben an, dass keine Interessenkonflikte bestehen.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Epilepsiezentrum Erlangen, Klinik für Neurologie, Friedrich-Alexander Universität, Erlangen, Deutschland

    H.M. Hamer & J.D. Lang

  2. Klinik für Neurologie und Epilepsiezentrum Hessen, Philipps-Universität, Baldingerstr., 35043, Marburg, Deutschland

    S. Richter, N. Watermann &  A. Strzelczyk

  3. Epilepsiezentrum Frankfurt Rhein-Main, Klinik für Neurologie, J. W. Goethe Universität, Frankfurt am Main, Deutschland

    A. Strzelczyk

Authors
  1. H.M. Hamer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.D. Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Watermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Strzelczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Strzelczyk.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamer, H., Lang, J., Richter, S. et al. Gesundheitsökonomie und Lebensqualität bei Epilepsie. Z. Epileptol. 28, 153–160 (2015). https://doi.org/10.1007/s10309-015-0424-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10309-015-0424-4

Schlüsselwörter

Keywords

Search

Navigation